Literature DB >> 29454748

Fatty Acid Binding Protein 4 (FABP4) Overexpression in Intratumoral Hepatic Stellate Cells within Hepatocellular Carcinoma with Metabolic Risk Factors.

Norimichi Chiyonobu1, Shu Shimada2, Yoshimitsu Akiyama2, Kaoru Mogushi2, Michiko Itoh3, Keiichi Akahoshi4, Satoshi Matsumura4, Kosuke Ogawa4, Hiroaki Ono4, Yusuke Mitsunori4, Daisuke Ban4, Atsushi Kudo4, Shigeki Arii4, Takayoshi Suganami5, Shoji Yamaoka6, Yoshihiro Ogawa7, Minoru Tanabe4, Shinji Tanaka8.   

Abstract

Metabolic syndrome is a newly identified risk factor for hepatocellular carcinoma (HCC); however, tumor-specific biomarkers still remain unclear. We performed cross-species analysis to compare gene signatures of HCC from human patients and melanocortin 4 receptor-knockout mice, which develop HCC with obesity, insulin resistance, and dyslipidemia. Unsupervised hierarchical clustering and principle component analysis of 746 differentially expressed orthologous genes classified HCC of 152 human patients and melanocortin 4 receptor-knockout mice into two distinct subgroups, one of which included mouse HCC and was causatively associated with metabolic risk factors. Nine genes commonly overexpressed in human and mouse metabolic disease-associated HCC were identified; fatty acid binding protein 4 (FABP4) was remarkably enriched in intratumoral activated hepatic stellate cells (HSCs). Subclones constitutively expressing FABP4 were established from a human HSC cell line in which expression levels of inflammatory chemokines, including IL-1A and IL-6, were up-regulated through NF-κB nuclear translocation, resulting in recruitment of macrophages. An immunohistochemical validation study of 106 additional human HCC samples indicated that FABP4-positive HSCs were distributed in tumors of 38 cases, and the FABP4-high group consisted of patients with nonviral and nonalcoholic HCC (P = 0.027) and with multiple metabolic risk factors (P < 0.001) compared with the FABP4-low group. Thus, FABP4 overexpression in HSCs may contribute to hepatocarcinogenesis in patients with metabolic risk factors by modulation of inflammatory pathways.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29454748     DOI: 10.1016/j.ajpath.2018.01.012

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

Review 1.  Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma.

Authors:  Shu Shimada; Shinji Tanaka
Journal:  Int J Clin Oncol       Date:  2022-05-28       Impact factor: 3.402

2.  Diseasome and comorbidities complexities of SARS-CoV-2 infection with common malignant diseases.

Authors:  Md Shahriare Satu; Md Imran Khan; Md Rezanur Rahman; Koushik Chandra Howlader; Shatabdi Roy; Shuvo Saha Roy; Julian M W Quinn; Mohammad Ali Moni
Journal:  Brief Bioinform       Date:  2021-03-22       Impact factor: 11.622

Review 3.  Fatty Acid-Binding Protein 4 in Cardiovascular and Metabolic Diseases.

Authors:  Masato Furuhashi
Journal:  J Atheroscler Thromb       Date:  2019-02-07       Impact factor: 4.928

4.  Metabolic Alteration in Hepatocellular Carcinoma: Mechanism of Lipid Accumulation in Well-Differentiated Hepatocellular Carcinoma.

Authors:  Hideo Suzuki; Motoyuki Kohjima; Masatake Tanaka; Takeshi Goya; Shinji Itoh; Tomoharu Yoshizumi; Masaki Mori; Mariko Tsuda; Motoi Takahashi; Miho Kurokawa; Koji Imoto; Shigeki Tashiro; Akifumi Kuwano; Masaki Kato; Seiji Okada; Makoto Nakamuta; Yoshihiro Ogawa
Journal:  Can J Gastroenterol Hepatol       Date:  2021-02-18

5.  AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma.

Authors:  Chenxi Ma; Wenyan Kang; Lu Yu; Zongcheng Yang; Tian Ding
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

6.  Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma.

Authors:  Yi-Chieh Yang; Ming-Hsien Chien; Tsung-Ching Lai; Min-Che Tung; Yi-Hua Jan; Wei-Ming Chang; Shih-Ming Jung; Ming-Huang Chen; Chun-Nan Yeh; Michael Hsiao
Journal:  J Biomed Sci       Date:  2021-04-22       Impact factor: 8.410

7.  Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma.

Authors:  Zeng-Hong Wu; Dong-Liang Yang; Liang Wang; Jia Liu
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

8.  Adipocyte Fatty Acid Binding Protein Promotes the Onset and Progression of Liver Fibrosis via Mediating the Crosstalk between Liver Sinusoidal Endothelial Cells and Hepatic Stellate Cells.

Authors:  Xiaoping Wu; Lingling Shu; Zixuan Zhang; Jingjing Li; Jiuyu Zong; Lai Yee Cheong; Dewei Ye; Karen S L Lam; Erfei Song; Cunchuan Wang; Aimin Xu; Ruby L C Hoo
Journal:  Adv Sci (Weinh)       Date:  2021-03-27       Impact factor: 16.806

9.  PPM1G promotes the progression of hepatocellular carcinoma via phosphorylation regulation of alternative splicing protein SRSF3.

Authors:  Dawei Chen; Zhenguo Zhao; Lu Chen; Qinghua Li; Jixue Zou; Shuanghai Liu
Journal:  Cell Death Dis       Date:  2021-07-21       Impact factor: 8.469

10.  Upregulation of cancer-associated gene expression in activated fibroblasts in a mouse model of non-alcoholic steatohepatitis.

Authors:  Masahiro Asakawa; Michiko Itoh; Takayoshi Suganami; Takeru Sakai; Sayaka Kanai; Ibuki Shirakawa; Xunmei Yuan; Tomomi Hatayama; Shu Shimada; Yoshimitsu Akiyama; Katsuhito Fujiu; Yutaka Inagaki; Ichiro Manabe; Shoji Yamaoka; Tetsuya Yamada; Shinji Tanaka; Yoshihiro Ogawa
Journal:  Sci Rep       Date:  2019-12-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.